Leerink Partners Reiterates "Market Perform" Rating for iTeos Therapeutics (NASDAQ:ITOS)

iTeos Therapeutics (NASDAQ:ITOS - Get Free Report)'s stock had its "market perform" rating reissued by stock analysts at Leerink Partners in a report issued on Wednesday,Benzinga reports. They currently have a $9.00 target price on the stock, down from their prior target price of $47.00. Leerink Partners' price objective would indicate a potential upside of 14.65% from the company's previous close.

A number of other brokerages have also weighed in on ITOS. HC Wainwright reaffirmed a "buy" rating and set a $46.00 target price on shares of iTeos Therapeutics in a research report on Thursday, March 6th. JPMorgan Chase & Co. lowered shares of iTeos Therapeutics from an "overweight" rating to a "neutral" rating and lowered their price objective for the stock from $15.00 to $8.00 in a research note on Tuesday. Wells Fargo & Company reduced their price target on shares of iTeos Therapeutics from $17.00 to $16.00 and set an "overweight" rating for the company in a report on Tuesday, April 29th. Finally, Wedbush reissued an "outperform" rating and set a $25.00 price objective on shares of iTeos Therapeutics in a report on Wednesday, March 5th. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to data from MarketBeat, iTeos Therapeutics has an average rating of "Moderate Buy" and a consensus target price of $20.80.

iTeos Therapeutics Price Performance

NASDAQ:ITOS opened at $7.85 on Wednesday. The firm has a market capitalization of $300.45 million, a price-to-earnings ratio of -2.49 and a beta of 1.39. The business has a 50 day simple moving average of $6.56 and a 200-day simple moving average of $7.43. iTeos Therapeutics has a 1 year low of $4.80 and a 1 year high of $18.70.

iTeos Therapeutics (NASDAQ:ITOS - Get Free Report) last issued its earnings results on Monday, April 28th. The company reported ($0.80) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.94) by $0.14. As a group, analysts expect that iTeos Therapeutics will post -3.49 earnings per share for the current fiscal year.

Institutional Trading of iTeos Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. BVF Inc. IL purchased a new position in shares of iTeos Therapeutics during the 4th quarter valued at about $17,856,000. JPMorgan Chase & Co. raised its position in iTeos Therapeutics by 342.7% during the fourth quarter. JPMorgan Chase & Co. now owns 2,068,796 shares of the company's stock valued at $15,888,000 after acquiring an additional 1,601,477 shares in the last quarter. Boxer Capital Management LLC acquired a new position in iTeos Therapeutics in the fourth quarter valued at approximately $7,272,000. Jacobs Levy Equity Management Inc. grew its stake in shares of iTeos Therapeutics by 347.9% during the 4th quarter. Jacobs Levy Equity Management Inc. now owns 922,134 shares of the company's stock worth $7,082,000 after purchasing an additional 716,271 shares during the period. Finally, Millennium Management LLC increased its holdings in shares of iTeos Therapeutics by 1,008.8% during the 4th quarter. Millennium Management LLC now owns 411,072 shares of the company's stock valued at $3,157,000 after purchasing an additional 373,999 shares in the last quarter. Institutional investors and hedge funds own 97.16% of the company's stock.

iTeos Therapeutics Company Profile

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.